What should you know about LCIS management?

Lobular carcinoma in situ, or LCIS, describes abnormal cells within the milk-producing lobules of the breast. Classic LCIS is generally treated as a marker of increased future breast cancer risk rather than an invasive cancer. Some related findings, including pleomorphic LCIS, may need a different surgical discussion because their features can be more concerning.

Management depends on the biopsy result, breast imaging, family history, inherited risk, age, other health conditions, and personal priorities. A team may review the tissue, imaging, and both breasts before recommending observation, additional tissue removal, risk-reducing medicine, or another approach.

Ask whether the pathology is classic LCIS or another lobular lesion, whether imaging matches the biopsy, and whether more tissue is needed. Agree on a schedule for clinical assessment and breast imaging. Discuss the benefits and side effects of [Risk-Reducing Endocrine Therapy](/treatments/risk-reduction-and-prevention/risk-reducing-endocrine-therapy/), including how other medicines or health conditions may affect the choice.

Keep records of breast symptoms, imaging dates, biopsies, family history, and medicines. [Follow-Up After Cancer Treatment](/treatments/survivorship-and-rehabilitation/post-treatment-surveillance/) may help explain how ongoing review is organised, although your LCIS plan should be tailored to you.

Contact your breast team for a new lump, nipple or skin change, bloody discharge, persistent focal pain, or a change that does not settle. After a biopsy, seek prompt advice for increasing redness, swelling, drainage, fever, heavy bleeding, or worsening pain. Urgent care is appropriate for severe illness or bleeding that will not stop.

Which type of LCIS is present? Does the imaging match the biopsy? Do I need another biopsy or excision? How often should I have breast examinations and imaging? What risk-reducing medicines could fit my health? What changes should I report between visits?